RVL Pharmaceuticals
Katerina G. has a wealth of experience in finance and accounting, with roles ranging from Accountant to Vice President at various companies including RVL Pharmaceuticals and J.H. Cohn LLP. Katerina holds a CPA and MBA, with degrees from Monmouth University and Kean University.
This person is not in any offices
RVL Pharmaceuticals
RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.